Head-to-head clinical analysis: CLINIMIX E 2 75 25 SULFITE FREE W ELECT IN DEXTROSE 25 W CALCIUM IN PLASTIC CONTAINER versus TRAVASOL 2 75 SULFITE FREE W ELECTROLYTES IN DEXTROSE 10 IN PLASTIC CONTAINER.
CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER vs TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clinimix E 2.75/25 provides amino acids for protein synthesis and dextrose for caloric support in parenteral nutrition. Amino acids serve as substrates for protein synthesis, while dextrose provides a source of glucose for energy metabolism, preventing catabolism and promoting anabolism.
Travasol 2.75% with electrolytes in dextrose 10% is a parenteral nutrition solution. Amino acids provide substrate for protein synthesis, dextrose supplies calories, and electrolytes maintain acid-base balance and osmotic equilibrium.
Intravenous administration: Adult dose based on protein and electrolyte requirements; typical infusion rate not to exceed 4 mg/kg/min of dextrose. Daily dose should not exceed 2.5 g/kg amino acids or 25 g/kg dextrose.
Intravenous infusion. Dosage depends on caloric and nitrogen requirements, generally 1-3 L per day in adults providing 4.25 g amino acids and 100 g dextrose per liter.
None Documented
None Documented
Amino acids: not applicable (endogenous turnover). Dextrose: ~1-2 hours (exogenous glucose). Electrolytes: dependent on renal function; not traditionally defined.
Not applicable as a single entity; components have variable half-lives. Dextrose has elimination half-life of ~2-4 hours; amino acids have variable half-lives based on individual metabolic rates.
Amino acids: renal elimination of metabolites and urea. Dextrose: metabolized to CO2 and water, exhaled via lungs. Electrolytes: primarily renal (90-95%), minor fecal (<5%). No significant biliary excretion.
Renal (primarily as unchanged drug and metabolites). Biliary/fecal excretion is negligible (<5%).
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution